MindLight™
The first antidepressant response test using brain-derived biomarkers

MindLight is the first-ever circular RNA-based response test designed to predict if a patient with Major Depressive Disorder (MDD) will respond to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment. Current standard of care involves a lengthy trial-and-error approach when evaluating a patient's responsiveness to medications for MDD. Circular Genomics is aiming to improve the standard of care by streamlining the treatment selection process with the MindLight Antidepressant Response Test.